South Carolina life sciences eyes next billion-dollar move
Key points:
- • South Carolina has proven it can land major investments like Octapharma’s, and the next test is whether homegrown companies can scale without leaving.
- • Universities feed the pipeline, and MUSC, Clemson, and USC are adding funds, venture studios, and mentor networks to keep spinouts moving.
- • Lab space, seed capital, and experienced executives are the bottlenecks that will decide whether the cluster becomes self-sustaining.
September 2026 — If SCbio President and CEO James Chappell has his way, the next big IPO or billion-dollar acquisition will carry a South Carolina life sciences name. Getting there means turning recruitment wins into companies that start, scale, and stay in the state.
Join us at caa’s upcoming leadership summits! These premier events bring together hundreds of public and private sector leaders to discuss the challenges and opportunities for businesses and investors. Find the next summit in a city near you!
The state has proven it can land major projects. Octapharma finalized plans in July for its first U.S. manufacturing site, a $1.5 billion project in Rock Hill with more than 1,500 jobs. The harder test is whether that momentum produces homegrown companies.
“If we are thoughtful and strategic, we are at the beginning of the growth of this industry in South Carolina, not at the end,” Chappell told Invest:.
The base is strong. SCbio’s 2026 economic impact report puts the industry’s annual impact at $20.1 billion, with more than 60,000 jobs paying an average of $102,996, a 70% premium over the average state job. Since 2019, life sciences employment in South Carolina has grown faster than in any other Southeastern state.
From recruiting to retaining
Chappell sees two distinct buyers. Large biomanufacturers weigh talent from technical colleges and research universities, cost of doing business, and quality of life. Early-stage companies ask harder questions about capital, lab space, and access to founders who have built and exited companies.
“The question is whether the pieces are here to scale a company as easily as in a traditional market,” he said.
The recruitment side is working. Arthrex grew from zero employees to about 2,000 after opening in the state, and PAI Pharma keeps reinvesting in Greenville. Geography helps: a company can run a wet lab in Charleston and manufacture 20 or 30 minutes away at lower cost.
Where commercialization stalls
Universities supply most of the pipeline. “The vast majority of life sciences companies come out of universities,” Chappell said.
The road from lab to patient is unforgiving. Nine out of 10 ventures fail, and founders must navigate the FDA, reimbursement, and business basics many scientists have never learned.
South Carolina life sciences institutions are building the missing layers. MUSC has launched two funds that provide seed and early venture capital to university companies. It also runs company-building and pitch deck programs and is developing a venture studio that pairs promising ideas with CEOs who know how to scale.
SCbio works with the South Carolina Research Authority and the state’s three R1 universities – Clemson, the University of South Carolina, and MUSC – to match early-stage founders with experienced mentors. MUSC brings depth in neuroscience, oncology, and medical devices. Clemson is leading in bioengineering and genomics, and USC is investing $350 million in a neuroscience research hospital.
The spillover test
Large projects matter most for what they attract. “Large investments plant a flag and show other suppliers and companies what is possible,” Chappell said.
TechBio shows the next layer forming. AI drug developer GNQ Insilico moved its North American headquarters and labs to Greenville this year. The company uses AI, quantum, and high-performance computing to predict whether a drug will work in humans, and in which patients, before clinical trials begin.
Other states are competing for the same companies, and Chappell warns against coasting. “We need thoughtful, aggressive partners and must keep doubling down because other regions are pursuing the same companies,” he said.
Octapharma’s production is not expected to start until the mid-2030s, and the next five years will show whether the cluster can sustain itself before then. Executives and site selectors should watch how many university spinouts close follow-on funding in-state and whether new lab space matches the universities’ research strengths. They should also track whether suppliers follow Octapharma to York County and if the wage premium holds as employment grows. The benchmark is Chappell’s own: a major exit with South Carolina roots.
Want more? Read the Invest: South Carolina report.
